Roche: FDA approves accelerated approval of Tecentriq
(CercleFinance.com) - Swiss pharma giant Roche announces that the US Food and Drug Administration (FDA) has approved the accelerated approval by Tecentriq (atezolizumab) associated with Abraxane, for people with metastatic triple-negative and PD-L1 positive breast cancer.
“The FDA approval of this Tecentriq combination is an important treatment advance for people with PD-L1-positive, metastatic triple-negative breast cancer, a disease with high unmet medical need,” said Sandra Horning, MD, Roche's Chief Medical Officer and Head of Global Product Development.
She added, “This Tecentriq combination is the first cancer immunotherapy regimen to be approved in breast cancer, representing a meaningful step forward in the understanding of this disease.”
Copyright (c) 2019 CercleFinance.com. All rights reserved.
“The FDA approval of this Tecentriq combination is an important treatment advance for people with PD-L1-positive, metastatic triple-negative breast cancer, a disease with high unmet medical need,” said Sandra Horning, MD, Roche's Chief Medical Officer and Head of Global Product Development.
She added, “This Tecentriq combination is the first cancer immunotherapy regimen to be approved in breast cancer, representing a meaningful step forward in the understanding of this disease.”
Copyright (c) 2019 CercleFinance.com. All rights reserved.